Brian Powell
Medical · Harker Heights, TXNPI 1437371663
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Boston Scientific at 39.5% of the total. Reporting peaked in 2021 at $222 and has fallen 93.3% since, to $15 in 2025. That places this record below the midpoint for medical clinicians in TX, where the typical reported total is $657.
Across 17 payments — averaging $26.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$181
- Sunovion Pharmaceuticals Inc.$163
- AbbVie$22
- GSK$19
- Amarin Pharma, Inc.$16
- Esperion Therapeutics, Inc.$15
- plus $42 from 3 others
What the payments were for
- Food & beverage$459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $181 |
| Sunovion Pharmaceuticals Inc. | 8 | $163 |
| AbbVie | 1 | $22 |
| GSK | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$459 in reported general payments places this provider in the 40th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $190 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $182 |
| Doxycycline Hyclate | 20 | $110 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $0 |
Paid to pharmacies, not to this prescriber.
Other medical in Harker Heights
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
- Radha BernanderKaty$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.